![Eskil Söderlind](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Eskil Söderlind
Amministratore Delegato presso Merozyne Therapeutics AB
Profilo
Dr. Eskil Söderlind is an Investment Director for LU Bioscience AB.
He holds a
PhD in molecular biology from Uppsala, an executive MBA diploma and is an associate professor at Lund University.
He has experience from the life science/biotech area.
Dr. Eskil Söderlind has held different management positions which have resulted in several inventions of platform technologies at established companies.
Additional experiences include global business development responsibilities, marketing/licensing operations and strategic analyses of Intellectual Property landscapes.
Posizioni attive di Eskil Söderlind
Società | Posizione | Inizio |
---|---|---|
Merozyne Therapeutics AB
![]() Merozyne Therapeutics AB Pharmaceuticals: MajorHealth Technology Merozyne Therapeutics AB develops and manufactures pharmaceutical products. The company was founded Madeleine Durbeej-Hjalt and Virginie Carmignac and is headquartered in Lund, Sweden. | Amministratore Delegato | - |
Precedenti posizioni note di Eskil Söderlind
Società | Posizione | Fine |
---|---|---|
Cytoguide ApS
![]() Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Direttore/Membro del Consiglio | 20/05/2014 |
Lund University Bioscience AB
![]() Lund University Bioscience AB Investment ManagersFinance Lund University Bioscience AB (LU Bio) is an investment firm located in Lund, Sweden. In May 2007, LU Bio was founded by the parent firm, Lund University Development AB. They specialize in early-stage investments within the life sciences segment. Lund University was founded by the Swedish government in 1666. The university has three main research areas: medicine and pharmaceuticals, globally sustainable societal development, and the life sciences. | Investitore di Private Equity | 31/12/2012 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Lund University Bioscience AB
![]() Lund University Bioscience AB Investment ManagersFinance Lund University Bioscience AB (LU Bio) is an investment firm located in Lund, Sweden. In May 2007, LU Bio was founded by the parent firm, Lund University Development AB. They specialize in early-stage investments within the life sciences segment. Lund University was founded by the Swedish government in 1666. The university has three main research areas: medicine and pharmaceuticals, globally sustainable societal development, and the life sciences. | Finance |
Cytoguide ApS
![]() Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Health Technology |
Merozyne Therapeutics AB
![]() Merozyne Therapeutics AB Pharmaceuticals: MajorHealth Technology Merozyne Therapeutics AB develops and manufactures pharmaceutical products. The company was founded Madeleine Durbeej-Hjalt and Virginie Carmignac and is headquartered in Lund, Sweden. | Health Technology |
- Borsa valori
- Insiders
- Eskil Söderlind